Equities

Biohaven Pharmaceutical Holding Company Ltd

Biohaven Pharmaceutical Holding Company Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)147.76
  • Today's Change0.150 / 0.10%
  • Shares traded435.73k
  • 1 Year change+30.82%
  • Beta1.0478
Data delayed at least 15 minutes, as of Aug 12 2022 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.

  • Revenue in USD (TTM)859.68m
  • Net income in USD-1.02bn
  • Incorporated2013
  • Employees928.00
  • Location
    Biohaven Pharmaceutical Holding Company Ltd215 Church StNEW HAVEN 06510-1803United StatesUSA
  • Phone+1 (203) 404-0410
  • Websitehttps://www.biohavenpharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BHVN:NYQ since
announced
Transaction
value
Channel Biosciences LLCDeal completed25 Feb 202225 Feb 2022Deal completed10.43%1.24bn
Data delayed at least 15 minutes, as of Aug 12 2022 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TriNet Group Inc4.80bn377.00m5.37bn3.50k15.557.2612.061.165.745.7472.9712.291.59--14.281,713,571.0012.528.5225.9221.8721.9519.137.866.00--38.290.39350.0012.548.2124.2640.650.00--
Terminix Global Holdings Inc2.09bn66.00m5.44bn11.70k85.332.2831.712.650.53510.526917.1220.050.462628.539.95178,974.401.390.69581.580.806140.7443.223.011.841.205.570.26830.004.28-5.72530.00-4.18-17.04--
FTI Consulting, Inc.2.86bn218.44m5.58bn7.05k26.403.4321.181.966.146.1480.2247.210.9617--3.26421,396.907.356.819.098.6431.0632.907.657.66--43.050.16160.0012.808.9311.5322.4018.87--
ExlService Holdings, Inc.1.26bn126.83m5.73bn37.40k46.978.4732.354.593.733.7337.1120.701.03326.235.9633,738.0710.287.6712.739.5837.3835.3410.038.642.10--0.29390.0017.1010.3528.2613.207.58--
Cerevel Therapeutics Holdings Inc0.00-279.88m5.91bn200.00--13.56-----1.90-1.900.003.050.00----0.00-56.68---62.08--------------0.1073-------51.97------
Western Union Co4.87bn888.80m6.28bn10.50k7.3814.215.891.312.232.2312.231.160.5477----463,342.8010.018.2312.1610.3443.6141.0918.2714.27--23.150.857447.094.88-1.338.2626.05-2.657.99
WEX Inc2.10bn193.45m7.26bn5.60k38.764.0714.773.504.284.2845.8340.790.1945--0.5717374,298.902.090.73273.491.1162.3462.4310.773.54--8.630.61790.0018.6312.82100.06-64.266.84--
Robert Half International Inc7.16bn682.88m8.52bn14.60k12.985.9811.981.226.176.1764.6813.392.52--7.16490,420.8024.0719.3742.5233.1442.6941.139.547.42--13.550.0032.8426.474.2495.4511.76-15.0911.55
Genpact Ltd4.25bn343.32m8.76bn109.60k26.605.0118.462.081.801.8022.239.540.8996--4.3538,737.267.277.589.6610.0435.0735.818.099.03--12.730.472321.028.439.3719.846.50-8.40--
Sarepta Therapeutics Inc835.18m-506.63m9.55bn840.00--13.62--11.86-5.87-5.879.818.300.29020.52195.04994,266.70-17.60-22.01-21.17-25.2085.1087.56-60.66-101.074.14-8.140.6025--29.96164.5124.43--41.17--
Nielsen Holdings PLC3.54bn570.00m9.90bn14.00k17.342.848.982.791.581.479.809.650.3222--6.90252,500.005.311.305.781.5063.6860.6316.464.10--3.520.6054170.374.14-11.12190.001.88-4.66-27.64
Biohaven Pharmaceutical Holding Co Ltd859.68m-1.02bn10.53bn928.00------12.23-14.82-14.8212.60-11.260.77031.453.30926,383.60-83.39-124.44-167.93-194.7485.63---108.26-477.811.59-2.382.53--626.91---10.41--131.21--
R1 RCM Holdco Inc1.56bn62.00m10.70bn10.20k127.183.9473.436.960.20480.20485.136.620.4966--6.92152,568.601.983.822.194.9021.9116.983.983.06--5.290.3943--16.0420.00-1,144.52--32.55--
Booz Allen Hamilton Holding Corporation8.62bn509.32m12.67bn29.30k25.2611.6018.971.483.813.8164.428.291.44--4.93294,342.508.589.9911.3213.7653.4853.765.946.13--8.260.716933.846.427.56-23.4212.398.2019.96
Data as of Aug 12 2022. Currency figures normalised to Biohaven Pharmaceutical Holding Company Ltd's reporting currency: US Dollar USD

Institutional shareholders

33.72%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20224.17m5.87%
Capital Research & Management Co. (World Investors)as of 31 May 20223.45m4.85%
1919 Investment Counsel LLCas of 31 Mar 20223.05m4.29%
Janus Henderson Investors US LLCas of 31 Mar 20222.69m3.79%
Marshall Wace LLPas of 31 Mar 20222.40m3.38%
Oracle Investment Management, Inc.as of 31 Mar 20222.06m2.90%
SSgA Funds Management, Inc.as of 31 Mar 20221.66m2.33%
Eventide Asset Management LLCas of 31 Mar 20221.64m2.30%
Capital Research & Management Co. (International Investors)as of 31 May 20221.57m2.21%
The Vanguard Group, Inc.as of 30 Jun 20221.29m1.82%
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.